Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in New Haven, Connecticut

This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1352
Shown on this page
12
Current sort
Recently updated
Location scope
New Haven, CT
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within New Haven, Connecticut. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 385–396 of 1,352 matching trials in New Haven, CT.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in New Haven

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Not applicable Interventional

Promoting Palliative Care for People With Heart Failure

NCT06933875
View directory record Official record
Conditions
Heart Failure, Palliative Care
Interventions
Clinical Decision Support Tool
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Completed Phase 2 Interventional Results available

The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery

NCT05676294
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Completed Not applicable Interventional

Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients

NCT04217551
View directory record Official record
Conditions
Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain
Interventions
Therapeutic Hypothermia
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
76
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Completed Not applicable Interventional Results available

Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)

NCT04180020
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
ID/LAB, TAU
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
New Haven, Connecticut • Hershey, Pennsylvania • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Recruiting Phase 3 Interventional

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

NCT06592924
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, ADT
Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
374
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 272 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Active, not recruiting No phase listed Observational

ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

NCT05388708
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Interventions
ECMO support, PROSpect protocolized therapies
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
14 Days to 20 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Active, not recruiting Phase 2 Interventional

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Available No phase listed Expanded access

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

NCT06948955
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
Interventions
Bezuclastinib, Sunitinib
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Recruiting Phase 3 Interventional

Cardiac Sarcoidosis Randomized Trial

NCT03593759
View directory record Official record
Conditions
Cardiac Sarcoidosis, Sarcoidosis
Interventions
Prednisone or Prednisolone, Methotrexate
Drug
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
New Haven, Connecticut • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544

NCT07563894
View directory record Official record
Conditions
Healthy
Interventions
PF-07799933 tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fed, PF-07799933 film-coated tablets fasted, PF-07799933 film-coated tablets following rabeprazole pretreatment fasted
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

NCT07508241
View directory record Official record
Conditions
Obesity, Overweight and/or Obesity, Overweight, Drug Interaction
Interventions
PF-08653944, Acetaminophen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Recruiting Phase 1 Interventional

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

NCT07465835
View directory record Official record
Conditions
T Cell Malignancies
Interventions
ELA026
Drug
Lead sponsor
Electra Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 15, 2026, 2:06 AM EST